First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial-Reference-Cited by-同舟云学术

First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial

Published:2012-02-21 Issue:6 Volume:106 Page:1027-1032
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Arrieta Ó,Medina L A,Estrada-Lobato E,Hernández-Pedro N,Villanueva-Rodríguez G,Martínez-Barrera L,Macedo E O,López-Rodríguez V,Motola-Kuba D,Corona-Cruz J F

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201244.pdf

Reference37 articles.

1. Antman KH ( 1980 ) Current concepts: malignant mesothelioma . N Engl J Med 303 : 200 – 202

2. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M ( 1991 ) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study . Cancer 67 : 2984 – 2987

3. Ashcroft T ( 1973 ) Epidemiological and quantitative relationships between mesothelioma and asbestos on Tyneside . J Clin Pathol 26 : 832 – 840

4. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G ( 2000 ) Caelyx in malignant mesothelioma: a phase II EORTC study . Ann Oncol 11 : 697 – 700

5. Baldini EH, Recht A, Strauss GM, DeCamp Jr MM, Swanson SJ, Liptay MJ, Mentzer SJ, Sugarbaker DJ ( 1997 ) Patterns of failure after trimodality therapy for malignant pleural mesothelioma . Ann Thorac Surg 63 : 334 – 338

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Curcuma longa extract inhibits migration by reducing MMP-9 and Rac-1 expression in highly metastatic breast cancer cells;Research in Pharmaceutical Sciences;2024-03

2. Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies;International Journal of Nanomedicine;2024-01

3. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug;Frontiers in Chemistry;2023-09-07

4. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers;Advanced Drug Delivery Reviews;2022-11

5. Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System;Current Drug Metabolism;2022-08